Castle Biosciences, Inc. (NASDAQ:CSTL – Get Free Report) insider Tobin Juvenal sold 17,310 shares of the company’s stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $29.31, for a total transaction of $507,356.10. Following the completion of the transaction, the insider owned 80,725 shares of the company’s stock, valued at approximately $2,366,049.75. This trade represents a 17.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Castle Biosciences Price Performance
CSTL stock opened at $31.18 on Wednesday. The company has a market capitalization of $952.55 million, a P/E ratio of -47.24 and a beta of 0.98. The company has a fifty day moving average price of $23.20 and a 200-day moving average price of $26.30. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.85 and a current ratio of 6.04. Castle Biosciences, Inc. has a 52-week low of $17.72 and a 52-week high of $44.28.
Castle Biosciences (NASDAQ:CSTL – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.34. The company had revenue of $99.86 million for the quarter, compared to analysts’ expectations of $86.23 million. Castle Biosciences had a negative net margin of 5.43% and a negative return on equity of 4.15%. As a group, equities analysts expect that Castle Biosciences, Inc. will post -1.29 EPS for the current year.
Analyst Upgrades and Downgrades
View Our Latest Report on CSTL
More Castle Biosciences News
Here are the key news stories impacting Castle Biosciences this week:
- Positive Sentiment: BTIG raised its price target to $44 from $40 and maintained a “buy” rating. The new target implies approximately 41% upside from the referenced share price, signaling continued confidence in Castle Biosciences’ growth outlook and diagnostic-testing business. BTIG raises Castle Biosciences price target
- Neutral Sentiment: A recent report highlighted an update involving Castle Biosciences’ diagnostics business, attracting attention among healthcare investors. The available information does not provide enough detail to determine whether the update materially changes revenue or earnings expectations. Castle Biosciences diagnostics update
- Negative Sentiment: Insiders reported substantial selling activity. Derek J. Maetzold sold 28,646 shares for roughly $867,000 across July 31 and August 3, while Tobin W. Juvenal sold 19,040 shares for approximately $556,000. The transactions reduced their reported holdings, which could raise concerns about insider conviction. However, all sales were executed under pre-arranged Rule 10b5-1 trading plans, making them a weaker bearish signal than discretionary open-market selling. Castle Biosciences insider sales filing
Institutional Investors Weigh In On Castle Biosciences
Several institutional investors and hedge funds have recently made changes to their positions in the business. Federated Hermes Inc. bought a new stake in Castle Biosciences in the fourth quarter worth approximately $26,000. Kemnay Advisory Services Inc. bought a new position in shares of Castle Biosciences during the 4th quarter worth approximately $35,000. Jones Financial Companies Lllp grew its position in shares of Castle Biosciences by 10,592.0% during the 1st quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock worth $54,000 after buying an additional 2,648 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Castle Biosciences by 26.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,418 shares of the company’s stock worth $55,000 after buying an additional 297 shares during the period. Finally, Russell Investments Group Ltd. increased its stake in shares of Castle Biosciences by 63.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 2,508 shares of the company’s stock valued at $57,000 after acquiring an additional 976 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.
About Castle Biosciences
Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.
The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.
Featured Stories
- Five stocks we like better than Castle Biosciences
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
- The AI Chip Blockade Is Creating a Shadow Market
- Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter
Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
